Influenza Vaccine Market Foreseen to Draw a Promising Growth of 4179 Million US$ by 2025 | Top Key Vendors - GSK, Sanofi, Novartis, Abbott, Pfizer, Aleph, CS Vaccine

This report provides in-depth study of "Global Influenza Vaccine Market 2020" using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Influenza Vaccine Market report also provides an in-depth survey of key players in the market organization.

The Global Influenza Vaccine Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Influenza Vaccine market size to maintain the average annual growth rate of 0.0168007503398 from USD 3629 Million in 2014 to USD 3815 Million in 2019, analysts believe that in the next few years, Influenza Vaccine market size will be further expanded, we expect that by 2025, The market size of the Influenza Vaccine will reach USD 4179 Million.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/227656 .

Major key factors driving the growth of the Global Influenza Vaccine Market are rapid growth in R&D activities, growing investment by companies for the development of influenza vaccine, technological advancements in recombinant DNA technology, large number of population with no immunization against influenza viruses in emerging economies, rising healthcare expenditure and increasing involvement of government and non-government organizations.

Through the statistical analysis, the report depicts the international Influenza Vaccine Market including capacity, production, production value, cost/profit, supply/demand and global import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2020-2025 market development trends of Influenza Vaccine industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out.

Global Key Vendors:

1 Sanofi-pasteur

2 Novartis

3 GSK

4 Abbott

5 Pfizer

6 CSL

7 Hualan Bio

8 Changchun Bio

9 Aleph

10 Sinovac

11 CS Vaccine

12 Tianyuan Bio

13 Tiantan Bio

14 Siobp and More.................

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on "Global Influenza Vaccine Market Report 2020" @ https://www.businessindustryreports.com/buy-now/227656/single .

Product Type Segmentation

1 Whole virus vaccines

2 Split virus vaccines

3 Subunit or surface antigen vaccines

4 Live attenuated (cold-adapted) virus vaccines

Industry Segmentation

1 CDC

2 Other

Latest Business News:

GlaxoSmithKline (GSK) (February 27, 2020) - GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma - GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the acceptance of a regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for the treatment of asthma in adults by the European Medicines Agency (EMA).

The submission is supported by the pivotal Phase III clinical study (CAPTAIN), conducted in 2,436 adult asthma patients across 15 countries whose disease remained inadequately controlled despite treatment with a combination of an inhaled corticosteroid and a long-acting ?2-agonist (ICS/LABA). The study met its primary endpoint, demonstrating a statistically significant improvement in lung function compared with the ICS/LABA, Relvar/Breo Ellipta.

There is currently no single inhaled triple therapy available for the treatment of asthma in Europe. Asthma, a chronic lung disease that inflames and narrows the airways, affects 358 million people worldwide. Even when adherent to ICS/LABA treatment, at least 30% of asthma patients continue to experience symptoms, indicating that they require further treatment.

Trelegy Ellipta was approved in the European Union in November 2017 for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) who are not adequately treated by an ICS/LABA combination, or a combination of LABA and long-acting muscarinic antagonist (LAMA). If approved this would be the first once-daily single inhaler triple therapy available for asthma and COPD.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/227656 .

Major Points in Table of Contents:

Global Influenza Vaccine Market Report 2020

1 Influenza Vaccine Product Definition

2 Global Influenza Vaccine Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Influenza Vaccine Shipments

2.2 Global Manufacturer Influenza Vaccine Business Revenue

2.3 Global Influenza Vaccine Market Overview

3 Manufacturer Influenza Vaccine Business Introduction

3.1 Sanofi-pasteur Influenza Vaccine Business Introduction

3.2 Novartis Influenza Vaccine Business Introduction

3.3 GSK Influenza Vaccine Business Introduction

3.4 Abbott Influenza Vaccine Business Introduction

3.5 Pfizer Influenza Vaccine Business Introduction

3.6 CSL Influenza Vaccine Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.